Award Data

DESCRIPTION (provided by applicant): This Phase II proposal is a continuation of our Phase I award, Lentiviral Vectors for TCR Immunotherapy Targeted to Melanoma. We have successfully achieved the milestones laid out in our initial application. We generated a lentiviral gene vector capable of expressing a T cell receptor (TCR) specific for the tyrosinase:368-376 epitope, and demonstrated the act ...

DESCRIPTION (provided by applicant): The objective of this proposal is to complete engineering development and pre-clinical testing of a transapical miniaturized ventricular assist device (tMVAD) to treat patients with less advanced heart failure (HF). HFis increasing worldwide and represents a major burden in terms of health care resources and costs. Despite advances in medical care, prognosis wi ...

Abstract Amyotrophic Lateral SclerosisALSis a universally fatal neurodegenerative disease that afflicts overout of everyindividualsProtein aggregation has been implicated as a primary driving force in ALS and multiple other neurodegenerative illnessesTDPis the principle component of the protein aggregates in ALSand TDPalso stands out as the only genetically defined ALS mutant gene that is also the ...

DESCRIPTION: Undesired platelet activation can be result of many common pathologies or interventions. Arterial thrombosis and the acute ischemic events that follow, such as myocardial infarction and stroke, are among the leading causes of death, incapacitation, and rising health care costs in the developed world. Therefore antiplatelet drugs have significant market share and clinical importance, ...

DESCRIPTION Undesired platelet activation can be result of many common pathologies or interventions Arterial thrombosis and the acute ischemic events that follow such as myocardial infarction and stroke are among the leading causes of death incapacitation and rising health care costs in the developed world Therefore antiplatelet drugs have significant market share and clinical importance ...

ABSTRACT Yellow fever virus (YFV) represents a mosquito-borne emerging/re-emerging human pathogen that causes 20- 50% mortality and is endemic in andgt;40 countries. The current live attenuated YFV vaccine was developed in 1936 and following the establishment of a virus seed lot system, it has not been modified or otherwise improved in over 50 years. According to the CDC, this vaccine causes 47 se ...

DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

Preceding Award: NCI Award 1R44CA192875-02 Project Summary: According to the Oral Cancer Foundation, about 50,000 people in the US will be newly diagnosed with oral cancer (OC) in 2017, causing 9,700 deaths[1]. OC is a severely neglected orphan disease with a lack of significant treatment advances in 4 decades[1]. Historically, OC has been present in heavy smokers and drinkers. However, more recen ...

Abstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...

ABSTRACT Among inhibitors of Gram+ DNA polymerases IIIC and IIIE, several compounds are active against multiple strains of the anaerobic Gram+ bacterium Clostridium difficile (Cdiff). The compounds appear to be selective for Cdiff compared with other Gram+ anaerobes and aerobes, and a lead compound - 2-(3,4-dichlorobenzyl)- 7-(5-morpholinylpentyl)guanine or 359E - is active orally in protecting h ...